Volume overload

Background

• Volume overload is a clinical syndrome of extracellular fluid (ECF) expansion due to excess total body sodium.
• It is a common ED presentation that requires identification of the underlying cause and targeted decongestion.

• Definition: expansion of extracellular fluid volume due to increased total body sodium content, leading to edema, pulmonary congestion, and/or third-space fluid accumulation
  • An increase in total body sodium raises plasma osmolality, triggering compensatory water retention
  • Clinically apparent edema typically requires >2.5 L of excess ECF
  • Serum sodium concentration can be high, low, or normal in volume-overloaded patients (despite increased total body sodium)
• Key distinction: Volume overload ≠ dehydration. Patients can be total-body volume overloaded but intravascularly depleted (e.g., cirrhosis, nephrotic syndrome)

Pathophysiology

• Reduced effective circulating volume (ECF within the arterial system effectively perfusing tissues) triggers neurohormonal activation
  • Activation of RAAS → renal sodium and water retention
  • Sympathetic nervous system activation → systemic vasoconstriction
  • ADH release → free water retention
  • Suppression of natriuretic peptides (ANP, BNP) → reduced sodium excretion
• Heart failure: reduced cardiac output → decreased effective circulating volume → neurohormonal activation → sodium/water retention
• Cirrhosis: splanchnic vasodilation → arterial underfilling → neurohormoral activation → sodium/water retention with third-spacing into peritoneum
• Nephrotic syndrome: hypoalbuminemia → decreased oncotic pressure → edema; also primary renal sodium retention via ENaC activation in collecting duct
• Renal failure: impaired GFR and tubular sodium excretion → direct sodium/water retention

Epidemiology

• Heart failure is the most common cause of volume overload presenting to the ED
  • >1 million HF hospitalizations annually in the US
  • In-hospital mortality 4-14%; 1-year post-discharge mortality up to 30%
• Cirrhosis with ascites, nephrotic syndrome, and ESRD are other major causes

Clinical Features

Symptoms

• Cardiac
  • Dyspnea (exertional → orthopnea → PND → dyspnea at rest)
  • Bendopnea (dyspnea within 30 seconds of bending forward)
  • Exercise intolerance, fatigue
  • Chest tightness
• Systemic
  • Weight gain (often 2-10 kg over days to weeks)
  • Abdominal distension, early satiety, nausea (hepatic/splanchnic congestion)
  • Extremity swelling

Signs

• Pulmonary congestion
  • Crackles/rales (may be absent in chronic HF due to lymphatic compensation)
  • Wheezing ("cardiac asthma")
  • Hypoxia, tachypnea
  • Pleural effusions (often right-sided or bilateral; isolated left-sided effusion should raise suspicion for non-cardiac cause)
• Systemic venous congestion
  • Elevated JVP (>8 cm H2O)
  • Hepatojugular reflux
  • Peripheral pitting edema (lower extremities, sacral in bedridden patients)
  • Ascites
  • Hepatomegaly, RUQ tenderness (hepatic congestion)
• Cardiovascular
  • S3 gallop (volume overload, systolic dysfunction)
  • S4 gallop (diastolic dysfunction)
  • Displaced PMI
  • Tachycardia (compensatory)
  • Hypertension (common; SBP >160 in ~50% of ADHF presentations) or hypotension (low-output HF, cardiogenic shock)
• Other
  • Cool extremities, delayed capillary refill (if low cardiac output)
  • Jaundice (congestive hepatopathy)

Differential Diagnosis

Cardiac

• CHF (HFrEF, HFpEF, HFmrEF)
• Acute coronary syndrome with LV dysfunction
• Valvular heart disease (acute MR, acute AR, severe AS)
• Cardiac tamponade (may present with congestion)
• Constrictive pericarditis
• High-output heart failure (thyrotoxicosis, severe anemia, AV fistula, Paget disease, beriberi)

Hepatic

• Cirrhosis with portal hypertension
• Budd-Chiari syndrome
• Hepatic sinusoidal obstruction syndrome

Renal

• Acute kidney injury (oliguric)
• Chronic kidney disease / ESRD
• Nephrotic syndrome
• Acute glomerulonephritis

Other

• Iatrogenic (IV fluid overload, blood transfusion)
• Pregnancy / preeclampsia
• Severe hypoalbuminemia (malnutrition, protein-losing enteropathy)
• Medication-related (NSAIDs, CCBs, thiazolidinediones, corticosteroids)
• DVT / venous insufficiency (unilateral edema — not true volume overload)
• Lymphedema (non-pitting — not true volume overload)
• Myxedema (hypothyroidism)

Evaluation

Workup

Tailor workup to suspected underlying cause

All patients

• BNP or NT-proBNP
  • BNP >400 pg/mL or NT-proBNP >900 pg/mL (age-adjusted) strongly suggests HF as cause
  • BNP <100 pg/mL or NT-proBNP <300 pg/mL makes HF unlikely
  • Falsely low in obesity; falsely elevated in renal failure, AF, PE, sepsis
• BMP/CMP — electrolytes, BUN, creatinine, glucose, calcium
• CBC — anemia (high-output HF), infection
• Urinalysis — proteinuria (nephrotic syndrome), casts (GN)
• ECG — ischemia, arrhythmia, LVH, low voltage (tamponade/effusion)
• CXR — cardiomegaly, cephalization, Kerley B lines, pleural effusions, pulmonary edema
• Pulse oximetry / ABG if respiratory distress

Cardiac suspected

• Point-of-care ultrasound (POCUS) — high yield in the ED
  • B-lines (≥3 per zone in ≥2 bilateral zones = pulmonary edema; LR+ ~7.4 for ADHF)
  • IVC assessment (dilated >2.1 cm with <50% collapsibility suggests elevated RA pressure)
  • LV function (gross EF estimation)
  • Pericardial effusion
  • Pleural effusions
• Troponin — rule out ACS as precipitant
• Hepatic function panel — congestive hepatopathy
• Lactate — if concern for cardiogenic shock or hypoperfusion
• TSH — if new HF or tachycardia-mediated

Hepatic suspected

• LFTs, albumin, INR
• Abdominal ultrasound with Doppler (portal hypertension, ascites)
• Paracentesis (if new ascites or concern for SBP) — cell count, albumin, culture, total protein, SAAG

Renal suspected

• Urine sodium
  • <10 mEq/L in HF, cirrhosis, nephrotic syndrome (avid renal sodium retention)
  • >20 mEq/L in renal failure (impaired tubular reabsorption)
• Urine protein/creatinine ratio or 24-hour urine protein
• Renal ultrasound
• Consider complement levels, ANA, ANCA if GN suspected

Diagnosis

• Volume overload is a clinical diagnosis supported by history, exam, and ancillary testing
• Identify the underlying cause — this drives specific management
• Assess hemodynamic profile using the Stevenson/Nohria classification for HF patients:
  • Warm and wet (adequate perfusion + congestion) — most common ADHF presentation (~70%)
  • Cold and wet (poor perfusion + congestion) — cardiogenic shock spectrum
  • Warm and dry (adequate perfusion + euvolemic) — compensated HF
  • Cold and dry (poor perfusion + euvolemic) — low-output state without congestion

Management

General Principles

• Identify and treat the precipitant — ACS, arrhythmia, medication nonadherence, dietary indiscretion, infection, PE, renal failure, uncontrolled HTN
• Treat respiratory distress first (airway management before diuresis)
• Obtain daily weights — best metric to follow decongestion progress
• Goal: net negative fluid balance of 1-2 L/day (weight loss 0.5-1 kg/day); may be more aggressive in acute pulmonary edema
• Sodium restriction (<2 g/day) and fluid restriction (1.5-2 L/day) if hyponatremic or refractory

Respiratory Support

• Supplemental O2 — titrate to SpO2 ≥90%
• Non-invasive positive pressure ventilation (NIPPV) — first-line for acute cardiogenic pulmonary edema
  • Reduces work of breathing, decreases preload and afterload, improves oxygenation
  • CPAP 5-10 cmH2O or BiPAP 10/5 cmH2O, titrate to effect
  • 3CPAP RCT demonstrated reduced mortality and intubation rates vs standard O2
• Intubation — if NIPPV fails, altered mental status, or inability to protect airway
  • Beware hemodynamic compromise with induction agents and positive pressure ventilation in patients with poor cardiac reserve

Vasodilators

For hypertensive volume-overloaded patients (SBP >110-120 mmHg), especially with acute pulmonary edema

• IV Nitroglycerin — drug of choice in acute cardiogenic pulmonary edema with adequate BP
  • Start 5-20 mcg/min, titrate q3-5 min up to 200 mcg/min
  • Reduces preload > afterload; improves coronary blood flow
  • High-dose NTG (bolus 200-400 mcg then infusion) can rapidly reduce pulmonary edema symptoms
  • Avoid if SBP <90, severe aortic stenosis, recent PDE5 inhibitor use
• IV Nitroprusside — arteriolar and venous dilation; useful if severe afterload excess
  • 0.3-0.5 mcg/kg/min; max 2-3 mcg/kg/min
  • Risk of cyanide toxicity, coronary steal; generally second-line
• Consider nicardipine or clevidipine if concomitant hypertensive emergency

Diuretics

Cornerstone of decongestion therapy

Loop Diuretics (First-Line)

• IV furosemide is the most commonly used agent
  • Diuretic-naive patients: Start 20-40 mg IV bolus
  • Chronic loop diuretic users: Give IV dose ≥ home oral daily dose (high-dose strategy preferred)
    • The DOSE trial showed high-dose IV furosemide (2.5× oral dose) provided greater symptom relief, diuresis, and weight loss vs. low-dose (1× oral dose), with only transient increases in creatinine
    • No significant difference between bolus q12h vs. continuous infusion on primary outcomes
  • Reassess urine output at 2 hours; if <100-150 mL/hr, double the dose
• Equivalent doses: furosemide 40 mg IV = bumetanide 1 mg IV = torsemide 20 mg IV
• Bioavailability: IV furosemide 100%, oral furosemide ~50% (variable; bumetanide and torsemide have more reliable oral absorption)

Diuretic Resistance (Sequential Nephron Blockade)

If inadequate urine output despite escalating loop diuretic dose

• Add thiazide-type diuretic for synergistic blockade at distal convoluted tubule
  • Metolazone 2.5-5 mg PO (give 30 min before loop diuretic) OR
  • Chlorothiazide 250-500 mg IV (if unable to take PO)
  • Monitor closely for hypokalemia, hyponatremia, hypomagnesemia
• Add acetazolamide — carbonic anhydrase inhibitor; blocks proximal tubular sodium reabsorption
  • The ADVOR trial (n=519) showed IV acetazolamide 500 mg daily added to loop diuretics significantly increased successful decongestion at 3 days (42.2% vs. 30.5%; RR 1.46, 95% CI 1.17-1.82; p<0.001), with shorter hospital stay and no difference in adverse events
  • Most effective in patients with elevated serum bicarbonate (metabolic alkalosis from chronic diuretic use)
  • Note: ADVOR excluded patients on SGLT2 inhibitors; interaction unknown
• Consider SGLT2 inhibitor (empagliflozin, dapagliflozin) — osmotic diuresis via glucosuria and natriuresis at proximal tubule; EMPULSE trial supports in-hospital initiation

Monitoring During Diuresis

• Urine output (Foley if ICU; monitor closely in ED)
• Daily weight (best metric)
• BMP q12-24h (K, Mg, Na, Cr) — replete K >4.0, Mg >2.0
• Reassess volume status clinically (JVP, lung exam, edema, orthopnea)
• Monitor for signs of over-diuresis: hypotension, worsening renal function, muscle cramps
• Transient rises in creatinine during diuresis ("pseudo-worsening renal function") are generally acceptable if patient is decongesting and hemodynamically stable

Inotropes

Reserved for "cold and wet" profile (low cardiac output + congestion) — cardiogenic shock spectrum

• Dobutamine — beta-1 agonist; increases contractility and cardiac output
  • Start 2.5-5 mcg/kg/min, titrate to effect
  • Shorter half-life, more easily titratable than milrinone
• Milrinone — PDE-3 inhibitor; inotrope + vasodilator ("inodilator")
  • Load 50 mcg/kg over 10 min (often omitted), then 0.375-0.75 mcg/kg/min
  • Renally cleared; accumulates in renal failure
  • Greater vasodilation → more hypotension risk than dobutamine
• Do NOT start or newly initiate beta-blockers in acute decompensation

Disease-Specific Management

Heart Failure

• See CHF
• Initiate or continue GDMT when hemodynamically stable (ARNI/ACEi/ARB, beta-blocker, MRA, SGLT2i)
• STRONG-HF trial supports rapid up-titration of GDMT post-discharge

Cirrhosis with Ascites

• Spironolactone is first-line (100 mg/day, max 400 mg/day) ± furosemide in 100:40 ratio
• Sodium restriction (<2 g/day)
• Large-volume paracentesis for tense ascites or respiratory compromise
  • Give albumin 6-8 g per liter removed if >5 L removed
• Avoid NSAIDs (worsen renal sodium retention)
• Avoid ACEi/ARBs (can precipitate hypotension and hepatorenal syndrome)
• Maintain MAP >82 mmHg to prevent hepatorenal syndrome

Nephrotic Syndrome

• Treat underlying cause
• Sodium restriction (<3 g/day), fluid restriction
• Loop diuretics (higher doses often needed due to albumin binding in tubular lumen)
• Add thiazide if refractory
• Avoid vigorous diuresis → risk of thromboembolism from hemoconcentration, AKI
• Albumin infusion + furosemide debated; may help in selected patients with severe hypoalbuminemia

Renal Failure

• Loop diuretics (higher doses needed as GFR declines)
• Avoid thiazides if GFR <30 (ineffective alone; may work synergistically with loops)
• Emergent dialysis/ultrafiltration indications:
  • Refractory pulmonary edema
  • Severe hyperkalemia
  • Severe metabolic acidosis
  • Uremic symptoms (pericarditis, encephalopathy, bleeding)

Iatrogenic Volume Overload

• Reduce or discontinue IV fluids
• Diuresis as above
• Reassess fluid strategy (most hospitalized patients do not need maintenance IVF)

Refractory Volume Overload

• Ensure adequate diuretic dosing before declaring refractory
• Maximize sequential nephron blockade (loop + thiazide + acetazolamide)
• Consider hypertonic saline with furosemide (emerging evidence, not yet standard)
• Ultrafiltration — mechanical fluid removal via venovenous access
  • UNLOAD trial showed benefit in fluid removal; CARRESS-HF showed no benefit over stepped pharmacological therapy and more adverse events
  • Reserve for truly refractory cases
• Early nephrology and/or advanced HF consultation

Medication Dosing

Furosemide 20-40mg IV bolus (diuretic-naive); or IV dose >= home oral daily dose IV Bumetanide 1-2mg IV (equivalent to furosemide 40-80mg) IV Metolazone 2.5-5mg PO 30min before loop diuretic PO Chlorothiazide 250-500mg IV IV Acetazolamide 500mg IV daily on top of loop diuretic IV Nitroglycerin 5mcg/min IV, titrate by 5-10mcg/min q5min (max 200mcg/min) IV

Disposition

Admit

• Acute pulmonary edema requiring IV diuretics, NIPPV, or intubation
• Hypotension or cardiogenic shock ("cold and wet")
• New-onset HF (requires workup for etiology)
• Significant electrolyte derangements
• ACS or arrhythmia as precipitant
• Inadequate diuretic response in ED
• Volume overload with renal failure requiring dialysis consideration
• Tense ascites requiring paracentesis with hemodynamic instability

ICU Admission

• Cardiogenic shock or need for vasopressors/inotropes
• Respiratory failure requiring intubation
• IV nitroprusside infusion
• Hemodynamically unstable with ongoing need for titrated infusions

Consider Discharge

• Mild exacerbation in known HF with preserved hemodynamics
• Adequate diuretic response in ED (symptom improvement, adequate urine output)
• Able to resume oral diuretics
• Reliable follow-up within 24-72 hours (STRONG-HF model supports close post-discharge follow-up)
• Stable electrolytes, renal function
• No acute precipitant requiring inpatient management
• Ensure medication reconciliation, dietary counseling, daily weight monitoring instructions, and clear return precautions

Discharge Checklist

• Restart/optimize GDMT (for HF patients)
• Adjusted diuretic regimen with clear instructions
• Daily weight log with action plan (call if >2 lb gain overnight or >5 lb in a week)
• Low-sodium diet education
• Fluid restriction if indicated
• PCP or cardiology follow-up within 7 days (ideally 24-72 hours post-discharge)

See Also

• CHF
• Pulmonary edema
• Cardiogenic shock
• Ascites
• Nephrotic syndrome
• Acute kidney injury
• Hypertensive emergency
• Diuretics

External Links

• EMCrit IBCC - Acute Decompensated Heart Failure
• Wiki Journal Club - DOSE Trial
• Wiki Journal Club - ADVOR Trial